{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:20:39Z","timestamp":1785860439399,"version":"3.56.0"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:00:00Z","timestamp":1726358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Direct\u2010acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment through their high cure rates and improved safety profiles. We aimed to evaluate the efficacy and safety, and identify the optimal combination, of DAAs for the treatment of chronic HCV. A retrospective study was conducted of 613 patients with chronic HCV who were treated with DAAs. Demographic, HCV genotype, treatment regimen, virological response, and adverse drug event (ADE) data were collected at the initial visit and 4, 8, 12, and 24\u2009weeks later. The rapid virologic response (RVR) and sustained virologic response (SVR) rates were 90.4% and 97.8% for HCV genotype 1, 89.2% and 98.7% for genotype 6, 92.8% and 99% for genotype 2, and 90.9% and 100% for mixed genotype 2\/6 or unspecified genotypes, respectively. There were no significant differences in the RVR and SVR rates for the various DAA regimens. The mean ALT, AST, and GGT activities decreased, and the PLT count increased during the treatments. ADEs occurred in 8% of the patients. The commonest ADEs were itching (3.1%), fatigue (1.8%), and dizziness (1.1%). None of the patients discontinued treatment because of an ADE. Posttreatment disease progression occurred in 7.7% of the patients, including liver fibrosis (3.6%), cirrhosis (1.1%), hepatocellular carcinoma (1.1%), and high alpha\u2010fetoprotein (AFP) (1%). The factors associated with the achievement of RVR were low viral load, the use of sofosbuvir\/ledipasvir or sofosbuvir\/daclatasvir regimens, and a treatment duration of 12\u2009weeks. No specific factors were found to be associated with the achievement of SVR. Posttreatment disease progression was associated with a high AFP and the use of sofosbuvir\/ledipasvir. Thus, DAAs are highly effective and well\u2010tolerated means of treating chronic HCV, and significantly improve patient outcomes. Their high efficacy and favorable safety profiles highlight the importance of early diagnosis and the use of personalized treatment strategies.<\/jats:p>","DOI":"10.1002\/prp2.70007","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T06:38:22Z","timestamp":1726468702000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High efficacy and safety of direct\u2010acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4151-7861","authenticated-orcid":false,"given":"Thong Duy","family":"Vo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine University of Medicine and Pharmacy at Ho Chi Minh City  Ho Chi Minh City Vietnam"},{"name":"Department of Gastroenterology University Medical Center Ho Chi Minh City  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Thi Thu","family":"Bui","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy University of Medicine and Pharmacy at Ho Chi Minh City  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3553-856X","authenticated-orcid":false,"given":"Huong Tu","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine University of Medicine and Pharmacy at Ho Chi Minh City  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh Thi Huong","family":"Bui","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy University of Medicine and Pharmacy at Ho Chi Minh City  Ho Chi Minh City Vietnam"},{"name":"Department of Pharmacy Thong Nhat Hospital  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,15]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2927"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/gastroent12020023"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2301291"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886314666191001151314"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09988-7"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036913"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i40.6094"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01463-18"},{"key":"e_1_2_13_10_1","unstructured":"Health V.M.o.Thong tu so 2065\/QD\u2010BYT ban hanh ngay 29\/04\/2021 ve Huong dan chan doan va dieu tri benh gan vi rut C. 2021: Ha Noi VietNam."},{"key":"e_1_2_13_11_1","volume-title":"Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection","author":"Organization, W.H","year":"2018"},{"key":"e_1_2_13_12_1","doi-asserted-by":"crossref","unstructured":"PawlotskyJ\u2010Met\u00a0al.EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series.2020;73(5):1170\u20101218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"e_1_2_13_13_1","volume-title":"Evaluate the Use of Direct\u2010Acting Antivirals in Treatment and the Quality of Life of Hepatitis C Patients at the Hospital for Tropical Diseases","author":"Thanh NTL","year":"2018"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01196-0"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2017.09.004"},{"issue":"1","key":"e_1_2_13_16_1","first-page":"41","article-title":"Real\u2010life efficacy of generic sofosbuvir\/ledipasvir for treatment of Iranian patients with chronic hepatitis C: a cohort study","volume":"11","author":"Sharafi H","year":"2020","journal-title":"Caspian J Intern Med"},{"key":"e_1_2_13_17_1","volume-title":"Efficacy and Safety of Sofosbuvir and Ledipasvir in Treating Chronic Hepatitis C Patients with Genotype 1 or 6 at the Ho Chi Minh City University Medical Center","author":"Bich NTN","year":"2020"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61793-1"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13305"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227424"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214795"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.015"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.011"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.12.028"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.027"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0018"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2016.0107"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2017.08.004"},{"key":"e_1_2_13_30_1","volume-title":"Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection: Web Annex 3.1: Adult Hepatitis C Virus Treatment Systematic Review","author":"Zoratti M.","year":"2018"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i24.2582"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:40:59Z","timestamp":1729165259000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,15]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/prp2.70007"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70007","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,15]]},"assertion":[{"value":"2024-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70007"}}